Mark G Wise

10PUBLICATIONS
3CO-AUTHORS
Infectious agentsDisease surveillanceMedical bacteriologyMicrobial geneticsMicrobial ecology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Aug 27, 2026
In Vitro Activity of Imipenem-Funobactam Against Clinical Isolates of Gram-Negative Bacilli.

|Jul 08, 2026
Long-term trends in ceftolozane-tazobactam susceptibility among gram-negative pathogens in the United States: a nine-year SMART analysis (2016-2024).

|Oct 28, 2025
Trends in Pseudomonas aeruginosa In Vitro Susceptibility to Ceftolozane/Tazobactam in Latin America: SMART Surveillance Program, 2016-2024.

Mark G Wise, James A Karlowsky, Thales J Polis

|Jan 09, 2025
Antimicrobial Activity of Imipenem/Relebactam and Comparator Agents Against Gram-Negative Isolates Collected From Pediatric Patients: SMART 2018-2022 Global Surveillance.

C Andrew DeRyke, Mark G Wise, Karri A Bauer

|Sep 18, 2024
Susceptibility of Gram-negative pathogens collected in Israel to ceftolozane/tazobactam, imipenem/relebactam and comparators: SMART 2018-22.

Mark G Wise, C Andrew DeRyke, Irina Alekseeva

|Sep 17, 2024
Cefepime-taniborbactam activity against antimicrobial-resistant clinical isolates of Enterobacterales and Pseudomonas aeruginosa: GEARS global surveillance programme 2018-22.

James A Karlowsky, Mark G Wise, Meredith A Hackel

Pageof 2

Frequent Collaborators

1 joint publications

Tsuyoshi Uehara

1 joint publications

Greg Moeck

1 joint publications

Jianguo Li